SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+9.57%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.65B
AUM Growth
+$1.65B
(+4.6%)
Cap. Flow
+$165M
Cap. Flow
% of AUM
10.04%
Top 10 Holdings %
Top 10 Hldgs %
69.29%
Holding
60
New
5
Increased
18
Reduced
9
Closed
10
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$47M |
| 2 |
Ascendis Pharma
ASND
|
$46.5M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$45.3M |
| 4 |
Sanofi
SNY
|
$33.9M |
| 5 |
Align Technology
ALGN
|
$17.5M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$29.8M |
| 2 |
Intuitive Surgical
ISRG
|
$18.1M |
| 3 |
iRhythm Technologies
IRTC
|
$17.6M |
| 4 |
United Therapeutics
UTHR
|
$16.2M |
| 5 |
Eli Lilly
LLY
|
$14.7M |
Sector Composition
| 1 | Healthcare | 99.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $407M | 24.17% | 2,073,124 | – | – |
|
2
Natera
NTRA
$23.1B
| $125M | 7.39% | 3,100,560 -2,400 | -0.1% | -$96.4K |
|
|
JBIO
3
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $110M | 6.54% | 3,758,686 | – | – |
|
|
4
Ascendis Pharma
ASND
$11.8B
| $108M | 6.38% | 880,800 +380,976 | +76% | +$46.5M |
|
|
5
Sanofi
SNY
$121B
| $95.2M | 5.65% | 1,965,475 +700,929 | +55% | +$33.9M |
|
|
CINC
6
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $74.6M | 4.43% | 6,073,949 -6,000 | -0.1% | -$73.7K |
|
7
Merck
MRK
$210B
| $66.9M | 3.97% | 603,356 +19,888 | +3% | +$2.21M |
|
8
Vera Therapeutics
VERA
$1.38B
| $61.6M | 3.65% | 3,181,442 | – | – |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $47M | 2.79% | +413,173 | New | +$47M |
|
|
10
Vertex Pharmaceuticals
VRTX
$100B
| $45.3M | 2.69% | +156,989 | New | +$45.3M |
|
11
AstraZeneca
AZN
$248B
| $41.6M | 2.47% | 613,673 -88,205 | -13% | -$5.98M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $40.8M | 2.42% | 394,643 +99,893 | +34% | +$10.3M |
|
|
RETA
13
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $37.7M | 2.24% | 992,029 +173,653 | +21% | +$6.6M |
|
14
Sarepta Therapeutics
SRPT
$1.78B
| $32.1M | 1.91% | 247,955 +106,515 | +75% | +$13.8M |
|
|
CTIC
15
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $27.7M | 1.64% | 4,606,527 +994,151 | +28% | +$5.97M |
|
|
INBX
16
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $27.4M | 1.62% | 1,110,183 +660,006 | +147% | +$16.3M |
|
|
17
United Therapeutics
UTHR
$13.8B
| $24.8M | 1.47% | 89,207 -58,357 | -40% | -$16.2M |
|
18
Cytokinetics
CYTK
$4.23B
| $23.3M | 1.38% | 508,930 +188,208 | +59% | +$8.62M |
|
|
KDNY
19
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $21.1M | 1.25% | 806,459 +518,558 | +180% | +$13.6M |
|
20
Zentalis Pharmaceuticals
ZNTL
$122M
| $20.2M | 1.2% | 1,004,045 +420,688 | +72% | +$8.47M |
|
|
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $19.4M | 1.15% | 176,545 +36,771 | +26% | +$4.04M |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $17.9M | 1.06% | 703,074 +178,072 | +34% | +$4.53M |
|
|
23
Align Technology
ALGN
$10.3B
| $17.5M | 1.04% | +83,100 | New | +$17.5M |
|
24
Immatics
IMTX
$619M
| $17.4M | 1.03% | 2,000,776 +1,468,260 | +276% | +$12.8M |
|
25
DexCom
DXCM
$29.5B
| $15.9M | 0.95% | 140,678 -65,270 | -32% | -$7.39M |
|